The UAE has implemented a major change to make medicines more available across the country. On February 24, 2026, the Emirates Drug Establishment activated a new rule under Federal Decree-Law No. 38 of 2024 requiring pharmaceutical companies to appoint more than one authorised agent for each medical product they sell. This stops any single company from having a monopoly and is a first-of-its-kind move in the country's healthcare sector.
Why the Change Was Needed
The main goal is to ensure essential medicines are always on pharmacy shelves. Previously, if the one authorised distributor faced supply chain issues or other problems, a medicine could completely disappear. Now, with multiple agents, the supply chain becomes stronger. If one agent runs into trouble, others can step in to keep the medicine flowing. Officials state this strengthens pharmaceutical security and helps the country respond faster to public health emergencies. It also promotes the UAE's business environment for pharmaceutical investment by diversifying distribution channels and preventing monopolistic practices.
What It Means for Patients
For residents, this rule brings two major benefits. First, fewer shortages. In recent years, patients struggled to access important diabetes drugs, weight loss medications, and psychiatric treatments due to supply disruptions. This new system creates backup supply chains to fix that. Second, having more than one distributor creates competition. Health experts believe this will lead to better logistics services and may help lower costs for patients over time as companies compete on service and pricing.
In short, the UAE is ensuring that when you need medicine, it is available, accessible, and more likely to be affordable.
No comments yet. Be the first to share your thoughts.